BBLG

Business Context and Reporting Period

Company: Bone Biologics Corp (BBLG)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Bone Biologics is a clinical-stage medical device company focused on bone regeneration in spinal fusion using its proprietary recombinant human protein, NELL-1. The lead product candidate, NB1 (NELL-1 combined with demineralized bone matrix), is being developed for lumbar spinal fusion. The company holds an exclusive worldwide license from the UCLA Technology Development Group (UCLA TDG).
Key Milestone: In 2024, the company initiated a first-in-man pilot clinical study in Australia for NB1, treating up to 30 subjects. This triggered a $100,000 milestone payment to UCLA TDG.

Key Financial Metrics

Capital Structure: As of December 31, 2025, there were 1,795,260 shares of common stock outstanding. The company completed a 1-for-6 reverse stock split effective June 10, 2025.

Material Changes vs. Prior Period

• Reduced R&D Spend: R&D expenses decreased by approximately 50% (from $2.13M to $1.06M) due to lower protein needs during the pilot clinical study phase.
• Increased G&A: G&A expenses increased by 4.1% (from $2.09M to $2.17M), primarily driven by the appointment of an independent director in late 2024.
• Capital Raises: In June 2025, the company completed a public offering raising net proceeds of approximately $4.35 million. Additionally, the company sold shares via its At-The-Market (ATM) facility for net proceeds of $347,549 in 2025.
• Warrant Liability: The change in fair value of warrant liability resulted in a gain of $3,967 in 2025, compared to a gain of $51,081 in 2024.

Guidance, Outlook, Risks, and Contingencies

Outlook and Liquidity:

• The company estimates operating expenditures for the next twelve months at $4.9 million.
• Management expects available cash ($5.3 million as of Dec 31, 2025) to fund operations into the fourth quarter of 2026.
• Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and the need for additional financing.

Regulatory Path:

• The NB1 device is classified as a Class III medical device requiring a Pre-Market Approval (PMA) from the FDA.
• The company intends to use data from the Australian pilot study to support a future U.S. pivotal clinical trial.

Key Risks:

• Capital Needs: Significant additional funding is required to complete pivotal trials and achieve FDA approval. Failure to raise capital could force the company to scale back or discontinue operations.
• Regulatory Approval: There is no assurance that clinical trials will succeed or that the FDA will grant PMA approval.
• Intellectual Property: The company relies on an exclusive license from UCLA TDG, which includes significant milestone payments (up to $8 million in diligence fees) and royalties upon commercialization.
• Stock Listing: The company faces risks regarding compliance with Nasdaq listing standards, including minimum bid price and market value requirements.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the $4.9 million operating expenditure estimate and the timeline for funding into Q4 2026.
• Clinical Trial Progress: Monitor enrollment rates and safety data from the Australian pilot study (up to 30 subjects) to assess readiness for a U.S. pivotal trial.
• Financing Plans: Review upcoming capital raise announcements, given the "substantial doubt" regarding going concern status.
• UCLA TDG Obligations: Track upcoming milestone triggers (e.g., $250,000 for pivotal study enrollment) and potential royalty obligations.
• Nasdaq Compliance: Monitor stock price and market value to ensure continued listing on the Nasdaq Capital Market.